Prosecution Insights
Last updated: October 04, 2026
Application No. 18/522,944

SYSTEMS AND METHODS FOR USING GENERIC ANATOMY MODELS IN SURGICAL PLANNING

Final Rejection §101§103
Filed
Nov 29, 2023
Priority
Mar 13, 2013 — provisional 61/779,805 +2 more
Examiner
SKIBINSKY, ANNA
Art Unit
1635
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Blue Belt Technologies Inc.
OA Round
5 (Final)
39%
Grant Probability
At Risk
6-7
OA Rounds
1y 8m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allowance Rate
269 granted / 689 resolved
-21.0% vs TC avg
Strong +29% interview lift
Without
With
+29.1%
Interview Lift
resolved cases with interview
Typical timeline
4y 6m
Avg Prosecution
30 currently pending
Career history
717
Total Applications
across all art units

Statute-Specific Performance

§101
33.8%
-6.2% vs TC avg
§103
29.5%
-10.5% vs TC avg
§102
4.7%
-35.3% vs TC avg
§112
26.4%
-13.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 689 resolved cases

Office Action

§101 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Information Disclosure Statement An IDS has not been filed in the instant application. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Priority of US application 61/779805 filed 3/13/2013 is acknowledged. Status of Claims Amendments to the claims filed 3/11/2025 are acknowledged. Claims 43-44 are new. Claims 1-24 are cancelled. Claims 25-44 are under examination. Double Patenting The rejection of claims 25-42 on the ground of nonstatutory obviousness-type double patenting over claims 1, 2, 5 and 7 of US 11,086,970 is withdrawn in view of the Terminal Disclaimer filed 3/11/2025. The rejection of claims 25-42 on the ground of nonstatutory obviousness-type double patenting over claims 1-4, 6 and 8 of US 11,862,348 is withdrawn in view of the Terminal Disclaimer filed 3/11/2025. Claim Rejections - 35 USC § 101 The rejection of claims 25-44 under 35 U.S.C. 101 is withdrawn in view of Applicant’s amendments filed 3/17/2026. Claim Rejections - 35 USC § 103 The instant rejection is maintained from the previous Office Action filed 8/26/2026. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claims 25-44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tuma et al. (US 2008/0319449) in view of Schumann et al. (Medical Engineering and Physics, vol. 32 (2010) pgs. 638-644) and further in view of Lang et al. (The Journal of Bone and Joint Surgery, vol. 93 (2011) pages 1296-1299). Tuma et al. teach a method for correcting changes in a patient bone including imaging the bone joint (Abstract)(i.e. receiving a representation of the patient bone), as in claim 25, 34 and 43. Tuma et al. teach providing a “base shape” of a bone joint to compare with the patient bone (par. 0007-0009) which can be statistical shape models or generic models (par. 0014-0015)(i.e. receiving a target bone model), as in claim 25, 34 and 43. Tuma et al. teach selecting and overlaying the target bone shape with the patent bone (Figure 1)(i.e. registering the patient bone to the target bone), as in claims 25, 34 and 43. Tuma et al. teach determining contour deviations of the bone joint by ascertaining contour distances between the base shape and the shape of the joint bone (par. 0008); Tuma et al. teach comparison with typical joint bone shapes (par. 0006) and standard shapes (par. 0024); Tuma et al. ascertaining contour deviations volumetrically (i.e. determining a morphological deviation) and detecting part of the bone that is to be removed; the volume can be output separately or in relation to the bone as an image in a computer assisted planning system (par. 0011 and Figure 1); Tuma et al teach determining the anomalies that should be removed (par. 0042)(i.e. based on the representation of the patient bone and the target bone model, determining a region of the patient bone that comprises a morphological deviation based on the level of disconformity between the patient and target bone model), as in claim 25, 34 and 43. Tuma et al. teach (par. 0042) that the “natural shape (for example, curves) of the bone (for example, in accordance with a standardized bone model) should be reproduced, wherein bone anomalies would be removed,” (i.e. based on the determined region, generating a surgical plan defining at least one volume, a shape, a location, or an orientation of a portion of bone to be removed from the determined region in reference to the target bone model), as in claims 25, 34 and 43. Tuma et al. teach inscribing a base shape (i.e. generic bone model) into the head of the femoral neck bone (par. 0014 and Figure 1); Tuma et al. also teach creating a new shape that has a natural bone shape by overlaying the base shape and bone model (par. 0024); the modified bone model with the natural shape would read on a “desired postoperative shape” (i.e. modifying the generic bone model to generate a target bone model having a desired postoperative shape), as in claim 43. Tuma et al. teach a data set representing a patient bone (Abstract) as taken from a CT scan (par. 0047) or x-ray (par. 0011)(i.e. medical image), as in claim 26 and 35. Tuma et al. teach the target bone is a shape-based model (Figure 1), statistical shape model and volumetric model (par. 0037), as in claim 27 and 36. Tuma et al. teach a data set representing a patient bone (Abstract) as taken from a CT scan (par. 0047) or x-ray (par. 0011)(i.e. medical image), as in claims 28 and 37. Tuma et al. teach displaying visual indicia indicating the volume to be removed on the patient bone (Figure 1 and par. 0011), as in claim 30 and 39. Tuma et al. teach standardized models or generic models (par. 0014-0015)(i.e. a desired postoperative shape or appearance), as in claim 31 and 40. Tuma et al. teach reshaping a femoral neck bone (par. 0039)(i.e. patient bone comprises a hip bone) and reshaping the socket part of the hip’s joint ball (i.e. acetabular rim)(Figure 1), as in claims 33 and 42. Tuma et al. teach determining the depth and rate of the abnormality and interference caused by the abnormality (par. 0043-0044); Tuma et al. teach using a and b angles as a minimal limit for defining the volume to be removed (par. 0037)(i.e. which suggests determining a level of disconformity violates a threshold), as in claim 44. Tuma et al. do not specifically teach a target bone model that is generated from bones corresponding to the patient bone from a group of subjects having normal bone anatomy, as in claims 25, 34 and 43. Tuma et al. do not teach in response to the disconformity, guiding by the computer system a surgical tool to alter the morphological deviation as in claims 25, 34 and 44. Tuma et al. do not specifically teach that the group of subjects from which the target bone is generated have at least common age, gender, ethnicity, body size or other common physical or demographic features, as in claims 29 and 38. Tuma et al. do not specifically teach guiding a robotic surgical cutting instrument to alter the determined region comprising a morphological deviation and that the surgical tool comprises a robotic surgical tool, as in claims 25, 32 and 41. Schumann et al. teach construction of a statistical shape model of a femur from seventeen bones (Abstract, par. 1) including normal bones (Abstract, par. 2). Schumann et al. teach a training population from seventeen cadaver bones that serve as ground truth surface models (page 642, col. 1, par. 1) used to construct the statistical shape model (page 642, col. 2, par. 5) and considered as the “normal group” (page 642, col. 2, par. 6). Schumann et al. teach that their method can construct a normal bone (page 644, col. 1, last paragraph), as in claims 25, 34 and 43. Schumann et al. teach that the femur from the seventeen cadavers (Abstract), using datasets from all female patients (page 638, col. 2, par. 1), and healthy patients (page 639, col. 1, par. 1)(i.e. having a common sex or physical feature), as in claims 29 and 38. Lang et al. teach computer assisted surgery in combination with surgeon guided as well and autonomous robotic systems for orthopedic surgery (Abstract); Lang et al. teach a robotic arm that resects the bone while the surgeon views a 3D model of the bone (page 1296, col. 2, lines 1-10 from bottom)(i.e. guiding by a computer system a surgical tool to alter the morphological deviation corresponding to the bone model), as in claims 25, 32, 34, and 41. It would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the generic, statistical bone model of Tuma et al. with the statistical shape model created from individuals with a normal bone, as taught by Schumann et al. Modifying the teachings of Tuma et al. with the statistical shape model generated for a normal bone as taught by Schumann et al. is merely a simple substitution of one known, equivalent element for another to obtain a predictable result, as set forth in KSR. The result is predictable because the statistical shape bone model of Schumann et al. would serve the same purpose and function as the base generic or statistical shape model implemented by Tuma et al., i.e. as the reference for altering a deviation in a patient bone. Using statistical shape models as references in bone surgery are well known to those of ordinary skill at the time of filing of the instant application. Schumann et al. also teach the need for statistical shapes in surgery (page 638, col. 1-2 and page 644, col. 1, par. 2). One of skill in the art would have had a reasonable expectation of success combing Tuma et al and Schumann et al. because both teach surgical planning with statistical shape bone models. It would have been further obvious to one of ordinary skill in the art at the time the invention was made to have combined the teachings of Tuma et al. and Schumann et al. for computer assisted surgery using bone models with the teachings of Lang et al. where the bone deviation is operated upon with a computer system that guides a robot. Lang et al. provide motivation by teaching that robot assisted surgery can improve surgical outcomes (Abstract, par. 3). One of skill in the art would have had a reasonable expectation of success at combing Tuma et al., Schumann et al. and Lang et al. because all teach computer-assisted surgical planning with bone models. Response to Arguments Applicant's arguments filed 8/26/2026 have been fully considered but they are not persuasive. Applicants argue (Remarks, page 7) that Tuma et al., Shumman et al. and Lang et al. do not teach the newly recited limitations drawn to “based on the determined region, generating a surgical plan defining at least one volume, a shape, a location, or an orientation of a portion of bone to be removed from the determined region in reference to the target bone model.” In response, Tuma et al. teach (par. 0042) that the “natural shape (for example, curves) of the bone (for example, in accordance with a standardized bone model) should be reproduced, wherein bone anomalies would be removed.” This reads on defining where a natural shape occurs relative to anomalies such that the anomalies could be removed. Tuma et al. therefore teach that there is a surgical plan to remove anomalies wherein at least the location, orientation and shape of the anomalies (i.e. bone to be removed) are known. Lang et al. teach computer assisted surgery in combination with surgeon guided as well and autonomous robotic systems for orthopedic surgery (Abstract); Lang et al. teach a robotic arm that resects the bone while the surgeon views a 3D model of the bone (page 1296, col. 2, lines 1-10 from bottom) It would be obvious to one of ordinary skill to use the information about the reproduced natural shape of the bone and the bone anomalies to be removed taught by Tuma et al. to guide the robotic system of Lang et al. to make the needed alterations by removing the bone anomalies using the robotic system. Additional Noted Art Hughes et al. US 2011/0257653 Ianotti et al. US 2012/0022657 Williams, Tomos G., et al. IEEE transactions on medical imaging 29.8 (2010): 1541-1559. Barratt, Dean C., et al. Medical image analysis 12.3 (2008): 358-374. Fleute, Markus, and Stephane Lavallee. International Conference on Medical Image Computing and Computer-Assisted Intervention. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. E-mail communication Authorization Per updated USPTO Internet usage policies, Applicant and/or applicant’s representative is encouraged to authorize the USPTO examiner to discuss any subject matter concerning the above application via Internet e-mail communications. See MPEP 502.03. To approve such communications, Applicant must provide written authorization for e-mail communication by submitting the following statement via EFS Web (using PTO/SB/439) or Central Fax (571-273-8300): Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application by video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file. Written authorizations submitted to the Examiner via e-mail are NOT proper. Written authorizations must be submitted via EFS-Web (using PTO/SB/439) or Central Fax (571-273-8300). A paper copy of e-mail correspondence will be placed in the patent application when appropriate. E-mails from the USPTO are for the sole use of the intended recipient, and may contain information subject to the confidentiality requirement set forth in 35 USC § 122. See also MPEP 502.03. Conclusion All claims are identical to or patentably indistinct from, or have unity of invention with claims in the application prior to the entry of the submission under 37 CFR 1.114 (that is, restriction (including a lack of unity of invention) would not be proper) and all claims could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anna Skibinsky whose telephone number is (571) 272-4373. The examiner can normally be reached on 12 pm - 8:30 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Anna Skibinsky/ Primary Examiner, AU 1635
Read full office action

Prosecution Timeline

Show 6 earlier events
Aug 26, 2025
Request for Continued Examination
Aug 28, 2025
Response after Non-Final Action
Dec 17, 2025
Non-Final Rejection mailed — §101, §103
Mar 17, 2026
Response Filed
Jun 01, 2026
Final Rejection mailed — §101, §103
Aug 26, 2026
Request for Continued Examination
Aug 27, 2026
Response after Non-Final Action
Sep 23, 2026
Final Rejection mailed — §101, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12723274
METHOD AND DEVICE FOR FIXED-POINT EDITING OF NUCLEOTIDE SEQUENCE WITH STORED DATA
5y 2m to grant Granted Sep 01, 2026
Patent 12725356
COMPUTATIONAL MODEL TO PERSONALIZE DEFIBRILLATION MECHANISM OF WEARABLE CARDIAC DEFIBRILLATOR
4y 7m to grant Granted Sep 01, 2026
Patent 12694953
SYSTEMS, METHODS, AND MEDIA FOR MOLECULE DESIGN USING MACHINE LEARNING MECHANISMS
4y 12m to grant Granted Jul 28, 2026
Patent 12694949
METHOD AND SYSTEM FOR ANALYZING SEQUENCES
2y 10m to grant Granted Jul 28, 2026
Patent 12620472
METHOD, APPARATUS, AND PROGRAM FOR EVALUATION OF ANY ONE OR BOTH OF HEALTH STATE AND GROWTH STATE OF LIVESTOCK ANIMAL
5y 7m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7
Expected OA Rounds
39%
Grant Probability
68%
With Interview (+29.1%)
4y 6m (~1y 8m remaining)
Median Time to Grant
High
PTA Risk
Based on 689 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month